Abstract：
Alemtuzumab is a potent lymphocyte-depleting immunotherapy used in solid organ transplan-tation (SOT), that is increasingly being applied in diverse lymphoproliferative disorders (LPDs). However, a significant toxicity limiting expanded usage is cytomegalovirus (CMV) infection, for which standardized preventive strategies exist in SOT but not in LPDs due to a poor understanding of infection risk in this population, with early LPD studies largely limited to stem cell transplantation. Using one of the most diverse arrays of LPDs studied to date, our retrospective cohort study of non-transplant patients receiving alemtuzumab over a ten-year period at a large regional cancer center examines the incidence and clinical profile of infected patients. Among 24 patients, we identified a composite CMV infection rate of 42% with a symptomatic rate of 21%. We also noted significant variations in preventive strategies, which alongside a high infection rate presents an opportunity to improve outcomes through further work in standardization.
摘要：
Alemtuzumab是一种有效的淋巴细胞消耗免疫疗法，用于实体器官移植（SOT），越来越多地应用于各种淋巴增生性疾病（LPDs）。然而,限制扩大使用的重要毒性是巨细胞病毒（CMV）感染，由于对该人群的感染风险了解不足，因此在SOT中存在标准化预防策略，但在LPD中却不存在。早期LPD研究主要限于干细胞移植。使用迄今为止研究的最多样化的LPD阵列之一，我们对在大型区域癌症中心接受阿仑珠单抗治疗10年的非移植患者进行的回顾性队列研究检查了感染患者的发病率和临床特征.在24名患者中，我们发现复合CMV感染率为42%,症状发生率为21%.我们还注意到预防策略的重大变化，这与高感染率一起提供了通过进一步标准化工作改善结果的机会。
